Democritus University of Thrace (DUTH)
Επιδημιολογική και οικονομική ανάλυση κόστους - συνεπειών της καινοτομίας στην υγεία κατά την περίοδο κρίσης στην Ελλάδα
Abstract
dc:descriptionBackground: Hematologic malignancies are inextricably linked to significant burden for the patient and the healthcare system. Despite the introduction of several novel pharmaceutical agents and the subsequent improvement of clinical outcomes in the management of hematological malignancies, the gap between efficacy results of randomized controlled clinical trials (RCT) and real-world effectiveness (RWE) is significant, mainly due to the heterogeneity of the populations. As a result, clinical outcomes in the real world may be deflated, while treatment costs do not always match up to the "theoretical value". Over the past decade, hematologists have increasingly deployed new technological and pharmaceutical tools in the management of relapsed/refractory multiple myeloma (RRMM). The aim of the study was to capture the aggregated clinical benefit related to the simultaneous entry of several new RRMM treatments in Greece and to indirectly compare the pharmacoepidemiological benefit versus treatment outcomes observed with prior standard of care. A secondary aim was to compare the clinical benefit before and after the introduction of the pharmaceutical "innovation" in terms of cost to the public health system. Materials and methods: After systematically mapping the gap between RCT-based efficacy versus RWE effectiveness, a non-interventional retrospective chart review pharmacoepidemiological study focused on firstly evaluating the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma, before analyzing findings in the context of real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, reasons for discontinuation, and the treatment duration per therapeutic algorithm. Direct treatment costs for novel RRMM agents were estimated for most-common approved dosage combinations using publicly available hospital prices. Findings were compared with lenalidomide-based 2nd line costs using 2018 hospital prices, which were adjusted for inflation. The incremental cost-benefit ratio was determined as €Mn per % of patient receiving 2nd line therapy to maintain PFS at 52 weeks. Results: Data from 107 patients were collected. The median follow-up was 2.0 years. Of the subjects who met the selection criteria for the second LOT, 72.2% maintained the PFS at 52 weeks. If we assume that an additional four patients who achieved CR maintained PFS at 52 weeks, the proportion of subjects rises to 77%. In the third-line setting, the PFS rate at 52 weeks was 63.5%. The mPFS across the first and second, the second, and the third LOTs were 26, 17, and 15 months, respectively. The ORR was 76.1% in the second and 69.7% in the third LOT. After non-response or progression, the main reason for drug discontinuation was treatment intolerability. The second-line ORR and the 52-week PFS rate were similar to previous real-world findings from the bortezomib/lenalidomide era. The cumulative mPFS across the second and third LOTs was higher than the respective mPFS across the first and second LOTs. Mean per-patient cost for 2nd line RRMM therapies amounted to €62.892,24. When compared to lenalidomide-based regimen costs and outcomes in Greece (SoC prior 2018), it was estimated that the cumulative expenditure attributed to novel agents was €2Mn for real-world 2nd line treatment duration for an additional 5% - 10% of patients to maintain PFS at 52 weeks. The total direct costs for the management of 2nd line MM patients in Greece was estimated at €27Mn (oncology drugs, hospitalizations, diagnostic tests and other healthcare resource use). Conclusion Despite its limitations, the methodology and findings from this study may be used in future clinical and economic evaluations across all hematological malignancies. Such methodology is presented to improve the health technology and risk-sharing decision frameworks for novel high-cost pharmaceutical agents.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Petrakis, Ioannis
- Πετράκης, Ιωάννης
Subjects
dc:subject × 20- Αιματολογικές κακοήθειες
- Πολλαπλούν μυέλωμα
- Φαρμακοεπιδημιολογία
- Φαρμακο-οικονομία
- Μελέτες πραγματικού κόσμου
- Hematological malignancies
- Multiple myeloma
- Pharmacoepidemiology
- Pharmacoeconomics
- Real world evidence
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Αιματολογία
- Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Clinical Medicine
- Medical and Health Sciences
- Hematology
- Health Sciences
- Health sciences, miscellaneous
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56291